Cleveland BioLabs (NASDAQ:CBLI) Stock Price Up 2.8%

Share on StockTwits

Cleveland BioLabs, Inc. (NASDAQ:CBLI) rose 2.8% during trading on Friday . The company traded as high as $1.54 and last traded at $1.54. Approximately 222 shares traded hands during trading, a decline of 96% from the average daily volume of 5,378 shares. The stock had previously closed at $1.50.

A hedge fund recently raised its stake in Cleveland BioLabs stock. Renaissance Technologies LLC boosted its stake in shares of Cleveland BioLabs, Inc. (NASDAQ:CBLI) by 2.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 293,416 shares of the biotechnology company’s stock after purchasing an additional 6,100 shares during the period. Renaissance Technologies LLC owned about 2.60% of Cleveland BioLabs worth $493,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 3.85% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Cleveland BioLabs (NASDAQ:CBLI) Stock Price Up 2.8%” was first published by Zolmax and is the sole property of of Zolmax. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://zolmax.com/investing/cleveland-biolabs-nasdaqcbli-stock-price-up-2-8/3114502.html.

Cleveland BioLabs Company Profile (NASDAQ:CBLI)

Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines.

Recommended Story: Balanced Fund

Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Stitch Fix Inc  Receives Consensus Recommendation of “Hold” from Analysts
Stitch Fix Inc Receives Consensus Recommendation of “Hold” from Analysts
Analysts Set $30.00 Price Target for RGC Resources Inc.
Analysts Set $30.00 Price Target for RGC Resources Inc.
SunCoke Energy Inc  Sees Large Growth in Short Interest
SunCoke Energy Inc Sees Large Growth in Short Interest
SSE PLC/S  Receives Consensus Rating of “Hold” from Brokerages
SSE PLC/S Receives Consensus Rating of “Hold” from Brokerages
Zacks: Analysts Expect 3D Systems Co.  to Announce -$0.04 Earnings Per Share
Zacks: Analysts Expect 3D Systems Co. to Announce -$0.04 Earnings Per Share
James Hardie Industries plc  Receives Consensus Rating of “Hold” from Brokerages
James Hardie Industries plc Receives Consensus Rating of “Hold” from Brokerages


 
© 2006-2019 Zolmax.